S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Endologix, Inc. stock logo
ELGX
Endologix
$0.07
$0.03
$0.22
$7.10
$1.41M0.731.28 million shs85,372 shs
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
$0.00
$0.00
$0.01
N/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
$3.57
+1.7%
$3.74
$2.70
$11.82
$6.97M2.2614,097 shs10,685 shs
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
$0.16
$4.22
$0.66
$10.77
$1.64M-1.237.68 million shs243,173 shs
Ra Medical Systems, Inc stock logo
RMED
Ra Medical Systems
$0.73
$0.52
$11.14
$3.19M-0.03197,480 shs77,500 shs
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Endologix, Inc. stock logo
ELGX
Endologix
0.00%0.00%0.00%0.00%0.00%
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
0.00%0.00%0.00%0.00%-98.00%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
+1.71%-3.25%-7.51%+12.97%-68.80%
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
+1.55%-1.68%+0.24%-30.92%-94.71%
Ra Medical Systems, Inc stock logo
RMED
Ra Medical Systems
0.00%0.00%0.00%0.00%-61.18%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Endologix, Inc. stock logo
ELGX
Endologix
N/AN/AN/AN/AN/AN/AN/AN/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/AN/AN/AN/AN/A
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Ra Medical Systems, Inc stock logo
RMED
Ra Medical Systems
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Endologix, Inc. stock logo
ELGX
Endologix
N/AN/AN/AN/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/A
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
N/AN/AN/AN/A
Ra Medical Systems, Inc stock logo
RMED
Ra Medical Systems
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Endologix, Inc. stock logo
ELGX
Endologix
$143.37M0.01N/AN/A$3.56 per share0.02
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
$5.90M1.20N/AN/A$13.18 per share0.27
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
$1.59M1.03N/AN/A$0.60 per share0.27
Ra Medical Systems, Inc stock logo
RMED
Ra Medical Systems
$10K0.00N/AN/A$4.29 per share0.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Endologix, Inc. stock logo
ELGX
Endologix
-$64.76M-$2.19N/AN/AN/A-44.65%-63.96%-13.26%N/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/A0.00N/AN/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
-$6.53M-$6.23N/AN/A-110.64%-31.31%-29.32%5/1/2024 (Estimated)
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
-$12.33MN/AN/AN/A-776.76%-161.38%-83.58%N/A
Ra Medical Systems, Inc stock logo
RMED
Ra Medical Systems
-$26.86M-$92.36N/AN/AN/AN/A-496.57%-344.49%N/A

Latest OBLN, ELGX, MDIT, RMED, and NURO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/22/2024Q4 2023
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/A-$1.43-$1.43-$1.43N/A$1.32 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Endologix, Inc. stock logo
ELGX
Endologix
N/AN/AN/AN/AN/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/AN/A
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
N/AN/AN/AN/AN/A
Ra Medical Systems, Inc stock logo
RMED
Ra Medical Systems
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Endologix, Inc. stock logo
ELGX
Endologix
0.29
0.39
0.28
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/A
16.80
15.55
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
N/A
1.86
1.86
Ra Medical Systems, Inc stock logo
RMED
Ra Medical Systems
N/A
2.86
2.85

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Endologix, Inc. stock logo
ELGX
Endologix
51.61%
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
19.40%
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
18.64%
Ra Medical Systems, Inc stock logo
RMED
Ra Medical Systems
11.00%

Insider Ownership

CompanyInsider Ownership
Endologix, Inc. stock logo
ELGX
Endologix
1.30%
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
85.40%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
4.40%
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
8.10%
Ra Medical Systems, Inc stock logo
RMED
Ra Medical Systems
18.62%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Endologix, Inc. stock logo
ELGX
Endologix
52819.17 millionN/AOptionable
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
69N/AN/ANot Optionable
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
261.99 million1.84 millionNot Optionable
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
210.02 millionN/ANot Optionable
Ra Medical Systems, Inc stock logo
RMED
Ra Medical Systems
145.37 million4.37 millionNot Optionable

OBLN, ELGX, MDIT, RMED, and NURO Headlines

SourceHeadline
Dietary Interventions Reduce CVD Risk in RA and SpADietary Interventions Reduce CVD Risk in RA and SpA
ajmc.com - March 8 at 7:57 PM
Alert1 Medical Alert System Review: What Experts Say (2024)Alert1 Medical Alert System Review: What Experts Say (2024)
forbes.com - February 20 at 9:27 PM
Ra Medical Systems Inc.Ra Medical Systems Inc.
thestreet.com - February 15 at 10:42 AM
Catheter Precision Inc (VTAK)Catheter Precision Inc (VTAK)
investing.com - February 11 at 11:09 PM
VTAK Catheter Precision, Inc.VTAK Catheter Precision, Inc.
seekingalpha.com - January 19 at 6:41 PM
What Is The Life Expectancy Of Rheumatoid Arthritis? A Review By DoctorsWhat Is The Life Expectancy Of Rheumatoid Arthritis? A Review By Doctors
msn.com - January 7 at 11:58 PM
Catheter Precision Receives Notice from NYSE American Regarding Late Filing of Quarterly Report on Form 10-QCatheter Precision Receives Notice from NYSE American Regarding Late Filing of Quarterly Report on Form 10-Q
finance.yahoo.com - August 25 at 6:53 PM
Reminder: Ra Medical Systems Announces Name and Ticker Symbol ChangesReminder: Ra Medical Systems Announces Name and Ticker Symbol Changes
finance.yahoo.com - August 17 at 9:15 AM
Ra Medical Systems, Inc.: Ra Medical Systems Announces Allowance of New Closure Device PatentRa Medical Systems, Inc.: Ra Medical Systems Announces Allowance of New Closure Device Patent
finanznachrichten.de - August 16 at 6:14 PM
Ra Medical Systems Announces Milestone Achievement for Electrophysiology DivisionRa Medical Systems Announces Milestone Achievement for Electrophysiology Division
finance.yahoo.com - August 7 at 12:14 PM
Ra Medical Systems, Inc.: Ra Medical Systems Announces Proposed Name and Ticker Symbol ChangesRa Medical Systems, Inc.: Ra Medical Systems Announces Proposed Name and Ticker Symbol Changes
finanznachrichten.de - August 2 at 8:13 AM
Ra Medical says demand is rising for its non-invasive electrophysiology mapping systemRa Medical says demand is rising for its non-invasive electrophysiology mapping system
massdevice.com - July 24 at 5:15 PM
Ra Medical Systems, Inc.: Ra Medical Systems Electrophysiology Division Has Increased Demand for its Non-invasive Mapping SystemRa Medical Systems, Inc.: Ra Medical System's Electrophysiology Division Has Increased Demand for its Non-invasive Mapping System
finanznachrichten.de - July 24 at 12:14 PM
Ra Medical System’s Electrophysiology Division Has Increased Demand for its Non-invasive Mapping SystemRa Medical System’s Electrophysiology Division Has Increased Demand for its Non-invasive Mapping System
finance.yahoo.com - July 24 at 12:14 PM
Ra Medical Systems, Inc.: RMEDs LockeT Device Utilized in Structural Heart ProceduresRa Medical Systems, Inc.: RMED's LockeT Device Utilized in Structural Heart Procedures
finanznachrichten.de - July 6 at 10:17 AM
RMEDs LockeT Device Utilized in Structural Heart ProceduresRMED's LockeT Device Utilized in Structural Heart Procedures
finance.yahoo.com - July 6 at 10:17 AM
Investing in Ra Medical Systems Inc (RMED): What You Must KnowInvesting in Ra Medical Systems Inc (RMED): What You Must Know
knoxdaily.com - July 5 at 6:18 PM
Ra Medical Systems, Inc.: RMEDs Electrophysiology Division Submits Data for CE Mark on LockeT Expects to Receive CE Mark in Third Quarter, 2023Ra Medical Systems, Inc.: RMED's Electrophysiology Division Submits Data for CE Mark on LockeT Expects to Receive CE Mark in Third Quarter, 2023
finanznachrichten.de - June 28 at 9:07 AM
RMEDs Electrophysiology Division Submits Data for CE Mark on LockeT Expects to Receive CE Mark in Third Quarter, 2023RMED's Electrophysiology Division Submits Data for CE Mark on LockeT Expects to Receive CE Mark in Third Quarter, 2023
finance.yahoo.com - June 28 at 9:07 AM
Ra Medical Systems, Inc.: Ra Medicals Electrophysiology Division Announces First Hospital to Complete 100 Procedures Using the VIVO SystemRa Medical Systems, Inc.: Ra Medical's Electrophysiology Division Announces First Hospital to Complete 100 Procedures Using the VIVO System
finanznachrichten.de - June 12 at 4:10 PM
Ra Medical’s Electrophysiology Division Announces First Hospital to Complete 100 Procedures Using the VIVO SystemRa Medical’s Electrophysiology Division Announces First Hospital to Complete 100 Procedures Using the VIVO System
finance.yahoo.com - June 12 at 4:10 PM
Medical Device Co. Completes Merger in Q1/23Medical Device Co. Completes Merger in Q1/23
investorideas.com - June 9 at 9:35 PM
Ra Medical Systems reports Q1 resultsRa Medical Systems reports Q1 results
msn.com - June 5 at 10:34 AM
Ra Medical Systems, Inc.: Ra Medical Systems Announces First Quarter ResultsRa Medical Systems, Inc.: Ra Medical Systems Announces First Quarter Results
finanznachrichten.de - June 2 at 9:16 PM

New MarketBeat Followers Over Time

Top Headlines

All Headlines

Company Descriptions

Endologix logo

Endologix

NASDAQ:ELGX
Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.
Medite Cancer Diagnostics logo

Medite Cancer Diagnostics

OTCMKTS:MDIT
Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida.
NeuroMetrix logo

NeuroMetrix

NASDAQ:NURO
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Obalon Therapeutics logo

Obalon Therapeutics

NASDAQ:OBLN
Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. Obalon Therapeutics, Inc. was incorporated in 2008 and is headquartered in Carlsbad, California.
Ra Medical Systems logo

Ra Medical Systems

NYSE:RMED
Ra Medical Systems, Inc develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. Ra Medical Systems, Inc is based in Fort Mill, South Carolina.